Strategies to Predict, Induce and Monitor Graft Tolerance in Kidney Transplantation
This activity consists of recorded presentations from the "27th Annual National Conference" held Oct. 15–17, 2018, in Minneapolis, Minn.
Patients who receive a kidney transplant are committed to lifelong systemic immunosuppressive therapy, which can be associated with long-term and serious complications. Thus, achieving graft tolerance is the “Holy Grail” of kidney transplantation. Evidence suggests that hematopoietic chimerism via combined bone marrow and kidney transplantation may be a safe and feasible approach for inducing tolerance in kidney transplant recipients.
In addition, recently identified biomarkers that can detect tolerant or nearly tolerant patients have the potential to guide decisions on minimizing or discontinuing immunosuppression. Other novel biomarkers can be used to monitor transplant patients for acute and chronic rejection, as well as predict the risk of rejection. This presentation will review emerging strategies to predict, induce and monitor graft tolerance in kidney transplantation.
This activity is provided by OptumHealth Education.
There was no commercial support received for this activity.
To view this activity, you will need Internet Explorer 7.0+ or Firefox 3.0+ with Windows Media Player 9+, RealPlayer 12+ or Adobe Flash Player 9+. Be sure to disable any pop-up blocking software prior to beginning this activity.
This activity is designed to meet the educational needs of case managers, nurses, pharmacists, pharmacy technicians, physicians and other health care professionals who are interested in graft tolerance in kidney transplantation.
At the end of this educational activity, participants should be able to:
- Describe graft tolerance in kidney transplantation.
- Discuss combined bone marrow and kidney transplantation as an emerging strategy to induce graft tolerance in kidney transplantation recipients.
- Review novel biomarkers that can identify tolerant or nearly tolerant patients, monitor for acute and chronic rejection, and predict the risk of rejection.
Joseph R. Leventhal, MD, PhD
Michael Abecassis, MD, MBA
J. Roscoe Miller Distinguished Professor
Departments of Surgery and Microbiology/Immunology
Feinberg School of Medicine, Northwestern University;
Chief, Division of Organ Transplantation
Northwestern Memorial Hospital;
Founding Director, Comprehensive Transplant Center
Sarah Chart, RN
Eden Prairie, MN
Dixon B. Kaufman, MD, PhD, FACS
Ray D. Owens Professor of Surgery
Chief, Division of Transplantation
University of Wisconsin School of Medicine and Public Health;
Rebecca Gleason, RN, CCM
Eden Prairie, MN
Tina Rydland, PharmD
Crystal Clear Rx
Crystal Wong, MD
President Propoint Medical Writing
Disclosures of relevant financial relationships
In accordance with the ACCME Standards for Commercial SupportSM, OptumHealth Education (OHE) requires all those involved in the development of activity content to disclose their relevant financial relationships. An individual has a relevant financial relationship if such person (or his/her spouse/partner) has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services relate to the activity content. OHE ensures that the content is independent of commercial bias.
Dr. Leventhal has indicated that he is on the speakers’ bureau for Veloxis; has stocks or other ownership interests in TRACT Therapeutics; has received grant/research support from Regenerex, LLC; and his spouse is an employee of Pfizer.
Ms. Chart and Ms. Gleason have indicated that they are employees of and own stock in UnitedHealth Group.
Dr. Wong has indicated that she has received grant/research support from MyoKardia.
The remaining activity faculty or planners have no financial relationships to disclose.
Method for calculating CE credit
CE credit was calculated by the complexity of content.
In support of improving patient care, OptumHealth Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the health care team.
Credit Designation Statements
The participant will be awarded up to 1.00 contact hour(s) of credit for attendance and completion of supplemental materials.
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts credit from organizations accredited by the ACCME and ANCC.
This activity is approved for 1.00 contact hour(s) ([0.10] CEU) in states that recognize ACPE.
Attending the full program will earn 1.00 contact hour(s).
Unique Activity Number(s): JA0007123-0000-19-029-H01-P/T
OptumHealth Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants (AAPA) accepts credit from organizations accredited by the ACCME.
The Commission for Case Manager Certification has approved this program for a maximum of 1.00 clock hour(s) for Certified Case Managers (CCM).
A certificate of attendance will be provided to learners upon completion of activity requirements, enabling participants to register with licensing boards or associations that have not been preapproved for credits. To apply for credit types not listed above, participants should use the procedure established by the specific organization with which they wish to obtain credit.
- 1.00 ACPE - Pharmacist
- 1.00 ACPE - Pharmacy Technician
- 1.00 AMA
- 1.00 ANCC
- 1.00 Attendance
- 1.00 CCMC - General
You must be logged into your account to participate in this activity. Get started by clicking “Begin/Continue” and viewing the “CE Info”; then follow the prompts at the bottom of the screen. At the end of the activity, you will be able to view, save or print your certificate of participation. A complete listing of all of your activities can be found under “My Account”, “My Activities.”